english

Second dose of J&J Covid jab increases protection to 94%, firm’s data shows

Johnson & Johnson has announced that a second shot of its Covid jab, administered around two months after the first, enhances the protection offered by the vaccine to 94% against moderate and severe cases of the virus in the US.

In a statement issued on Tuesday, the pharmaceutical company released new data showing the increased efficacy of the vaccine after administering a top-up dose, with antibody levels rising four to six times higher than after the first. When given six months after the first dose, however, antibody levels climbed up twelve-fold.

The firm’s Chief Scientific Officer Paul Stoffels stressed the importance of the single-shot J&J jab in fighting the global pandemic and “protecting as many people as possible against hospitalization and death.” However, Stoffels praised the recent evidence supporting the booster shot’s enhanced coverage.

As per the statement, the safety profile of the vaccine remained consistent and generally well tolerated as a booster dose.

J&J says it has submitted its data to the US Food and Drug Administration (FDA) and it plans to give its recent findings to the World Health Organization (WHO), as well as other regulators globally.

Also on rt.com

FILE PHOTO: A dose of the Pfizer Covid vaccine is administered at a clinic at Ohio State University in Columbus, Ohio, September 15, 2021 © REUTERS/Gaelen Morse
FDA advisory panel votes AGAINST vaccine booster shots for all, approves for over-65s and high-risk

On Friday, the FDA recommended third shots of Pfizer’s mRNA vaccine for people at higher risk from coronavirus and citizens over the age of 65. However, the panel stopped short of mass-authorizing boosters of Pfizer’s jab.

Rival mRNA vaccine developer Moderna has also been pushing for boosters, with the firm releasing a study last week to show that its shot’s efficacy wanes over time, making a claim that top-up doses could be beneficial.

The efficacy of the single-shot J&J jab was found to be lower than other vaccines at 66%, according to results from its phase-three trials. Meanwhile, the protection offered by the two-dose mRNA vaccines produced by Pfizer-BioNTech and Moderna stood at 95% and 94.5%, respectively.

Also on rt.com

(L) © REUTERS/Dado Ruvic; (R) © REUTERS/Yves Herman
EU drugs regulator recommends flagging new possible adverse reactions to J&J Covid jab on product label

Think your friends would be interested? Share this story!

source: RT




Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.

(Visited 14 times, 1 visits today)
Avatar
Marius Leontiuc
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica, Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
http://www.leontiucmarius.wordpress.com/cv

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *